Concurrent BRAF/MEK Inhibitors in BRAF V600-Mutant High-Grade Primary Brain Tumors

Area of Science:

• Neuro-oncology
• Molecular oncology
• Cancer therapeutics

Background:

• BRAF V600 mutations are increasingly detected in primary brain tumors.
• Standard treatments like radiation and temozolomide are often ineffective for these mutations.
• Preclinical data suggest combined BRAF and MEK inhibition may be effective for MAP kinase pathway suppression in gliomas.

Observation:

• Two patients with malignant brain tumors harboring BRAF V600E mutations were treated with dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor).
• Both patients had tumors resistant to conventional therapies (radiation and temozolomide).

Findings:

• One patient with anaplastic pleomorphic xanthoastrocytoma achieved a partial response lasting 14 months, with tumor shrinkage and clinical improvement, before progression.
• The other patient with glioblastoma maintained stable disease for 16 months on the combined targeted therapy.

Implications:

• Concurrent BRAF and MEK inhibition demonstrates potential as a targeted treatment strategy for BRAF V600E-mutated primary brain tumors.
• These findings provide a basis for further clinical investigation into response rates, durability, and survival benefits.
• The study highlights the urgent need for novel therapeutic approaches in treating aggressive brain cancers.